SecBot SecBot
COURT-RULING ·Filed Mar 31, 2026

GSK

GSK plc
NEUTRAL
Impact 3/10
Horizonmonths Processed4mo ago CourtCourt Ruling · courtlistener.com
Court ruling (district)
Actionable Insight • Neutral

This procedural ruling does not change the fundamental case risk for GSK. The antitrust litigation continues in discovery; monitor for any future summary judgment motions or settlement discussions. The ruling may delay case progression but has no immediate financial impact.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$54.99
T+0 close · Apr 1, 2026 · via day close
Latest settled
−4.82%
T+60 · $52.34
Vs SPY
−18.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $54.99entry
  2. T+1 · 8mo ago +1.25%α +1.16% · $55.67
  3. T+5 · 7mo ago +4.23%α +0.47% · $57.31
  4. T+20 · 7mo ago −6.57%α −16.25% · $51.37
  5. T+60 · 5mo ago −4.82%α −18.20% · $52.34
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

In the long-running Lamictal reverse-payment antitrust case, the District Court for the District of New Jersey vacated a magistrate's order that had permitted five new expert reports from GSK and Teva without reviewing their content. The court found the magistrate's decision clearly erroneous and remanded for further proceedings, requiring the magistrate to assess whether the reports were within the scope of the scheduling order. This procedural setback for GSK increases uncertainty but does not resolve the underlying antitrust claims.

Court Ruling Details

Ruling Date
Mar 31, 2026
Court
District Court, D. New Jersey
Court Level
District
Judge
Jamel K. Semper
Case Type
antitrust
Ruling Type
procedural
Outcome
PARTIAL: mixed ruling, some claims won/lost
Precedent Risk
LOW

Key Facts

  • District court vacated magistrate's order allowing new expert reports without content review
  • Case involves allegations of illegal reverse-payment settlement to delay generic Lamictal
  • Matter remanded to magistrate for further proceedings to determine if reports comply with scheduling order

Financial Impact

No monetary damages awarded; procedural ruling on expert discovery

Risk Factors

  • Potential adverse antitrust ruling if case proceeds to trial or settlement
  • Discovery may expand scope of liability or damages

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-1lfpt4w0-GSK

US Market Status

Market Closed · Opens in 9h 13m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published Jul 2, 2026